XOMA Royalty Corporation Common Stock
XOMAXOMA Royalty Corporation (XOMA) is a pharmaceutical company that specializes in acquiring and managing royalties from innovative biopharmaceutical products. The company focuses on generating revenue through royalties and licensing agreements derived from its portfolio of biotechnology innovations. It provides investors with exposure to the success of various therapeutic products developed by partner companies in the biotech and pharmaceutical sectors.
Company News
Mural Oncology has completed a scheme of arrangement with XOMA Royalty, where XOMA will acquire the entire issued share capital of Mural. The transaction became effective on December 5, 2025, with share trading cancellation and shareholder consideration distribution expected soon.
Mural Oncology announced the final details of its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty, with a total cash consideration of $2.035 per share. The acquisition is expected to close in early December 2025, subject to Irish High Court sanction.
XOMA Corporation, a biotechnology company, announced that it will change its name to XOMA Royalty Corporation, effective July 10, 2024. The rebranding reflects the company's focus on pharmaceutical royalties.
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs.
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
